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Abstract Mucosal barrier disorders play an important
role in the pathomechanism of the allergic disease. A new
approach for their treatment uses liposomes, which consist
of phospholipids that make up 75% of the protective nasal
surfactant layer. Our aim was to investigate the eYcacy of
liposomal-based therapy, as a comprehensive treatment
alternative to guideline cromoglycate-based therapy, in the
treatment of seasonal allergic rhinoconjunctivitis (SAR).
We compared nasal and conjunctival symptom reduction
with LipoNasal n nasal spray used as monotherapy (LNM),
or LipoNasal n nasal spray and Tears Again eye spray com-
bination therapy (LTC), against standard cromoglycate
combination therapy (CGC). This prospective, controlled,
open observational study was conducted monocentrically.
According to their symptoms and preferences 72 patients
with SAR were distributed in three equal groups. The study
comprised two visits at an interval of 7 days. The eYcacy
was examined by daily documenting nasal and conjunctival
symptom scores. The Nasal-Spray-Sensory-Scale and the
Eye-Drops/Spray-Sensory-Scale were used to investigate
the tolerability. Quality of life (QoL) was evaluated, using
the RHINASTHMA QoL German adapted version. LNM
achieved signiWcant improvement in nasal (p < 0.001) and
conjunctival symptoms (p = 0.050). The symptom reduc-
tion using CGC was equally signiWcant. LTC led to signiW-
cant nasal symptom relief (p = 0.045). QoL did not improve
signiWcantly in all groups (p > 0.05). The tolerability of all
treatments was good and no adverse reactions were
observed. In all treatment groups the improvement of the
nasal and conjunctival symptom scores exceeds the mini-
mal clinically important diVerence (MCID). The results
demonstrate good tolerability and eYcacy of non-pharma-
ceutical liposomal-based treatment (LipoNasal n and Tears
Again), given as monotherapy or combination therapy, for
nasal and conjunctival symptoms caused by SAR. This
study indicates that liposomal-based treatment for SAR
may be a comparable alternative to cromoglycate therapy.
Further studies are needed to verify these Wndings.
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Introduction
A new approach for treating mucosal barrier disorders,
which are an important part of the pathomechanism of
allergic disease, uses liposomes, which consist of phospho-
lipids that make up 75% of the protective nasal surfactant
layer [1, 2]. These integrate into damaged cell membranes,
protecting upper airways against pathogens [3–5] and thus
stabilize respiratory barriers and strengthen their anti-
inXammatory and wound-healing capacities [3,  6,  7]. A
number of recent studies [8–10], practically demonstrate
that the symptoms of seasonal allergic rhinitis (SAR) are
eVectively reduced by nasal application of liposomes,
which have been available in the German pharmaceutical
market since 2007 [10], on an inXamed nasal mucosa. In
the open, mono-centric, prospective study conducted by
Weston (2010) [8], LipoNasal, a liposomal nasal spray, led
to a signiWcant reduction of SAR symptoms and an
improvement of quality of life, comparable to the eVect of a
standard treatment with an antihistamine/glucocorticoster-
oid spray. We decided to elaborate this interesting area, and
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assess liposomal-based monotherapy or combination ther-
apy as comprehensive treatment alternatives to the standard
guideline therapy for treating conjunctival and nasal symp-
toms experienced in SAR. We compared the eYcacy and
tolerability of a cromoglycate-based combination therapy
(Cromoglycate) speciWed by guidelines against a liposomal
nasal spray (LipoNasal n), alone or combined with Tears
Again eye spray, in an open, monocentric, prospective
study. The present study was carried out according to good
clinical practice. As both the monotherapy and combination
therapies are in accordance with the labelling the approval
by an ethics committee was not mandatory. Nevertheless,
the responsible ethics committee was consulted with
respect to professional regulations.
Materials and methods
Study design
The study, conducted from July to August 2009, was an
open-label, prospective, controlled, observational study
with 72 patients aged 18–69 years, with SAR, triggered by
grass, crop and/or herbal pollens, diagnosed by skin-prick
test. The study had a treatment and observation period of
1 week per patient, with two visits to the study centre at day
0 (Round 1) and day 7 (Round 2).
Patient allocation and medication
According to the observational study design an approved
consent was taken from each patient. Those patients that
gave their informed consent prior to their inclusion in the
study were allocated by the principal investigator into three
treatment groups, 24 patients in each group, treated with
either of two combination therapies or one monotherapy,
depending on their symptoms, preference and the expected
compliance. Patients, suVering from late pollen-induced
SAR, were Wrst oVered a standard therapy combination
based on guideline (1) cromoglycate combination therapy
(CGC) with cromoglycate eye drops and nasal spray.
Those patients having reservations towards pharmaco-
logical therapy were alternatively oVered medicinal prod-
ucts based on liposomal suspensions, choosing between (2)
LipoNasal n nasal spray and Tears Again eye spray combi-
nation therapy (LTC) (3) LipoNasal n nasal spray as mono-
therapy (LNM).
Tears Again is a liposomal spray to be applied on the
closed eyelids and originally is not designed for treatment of
allergies. Its intended use is to stabilize the tear Wlm lipid layer
in case of a tear Wlm deWciency, which is associated, e.g., with
allergic conjunctivitis, so that it may provide relieve of symp-
toms by stabilization of the natural tear Wlm system.
LipoNasal n (LipoNasal new) hay fever spray, a new for-
mulation with a reduced menthol fraction (0.004%), and
Tears Again eye spray are products of “Optima Pharma-
zeutische GmbH, Moosburg”. The liposomes consist of
highly puriWed soya lecithin, which contains at least 94%
phosphatidylcholine and other phospholipids. Medication
was applied according to the package instructions. Patients
applied LipoNasal n 2–3 times/nare/day (0.4–0.6 ml of lipo-
some suspension/day) and Tears Again 2–3 times/eye/day.
The active ingredient of CGC (HEXAL AG, Holzkir-
chen, Germany), is sodium cromoglycate. Its daily dose is
11.2–16.8 mg (0.56–0.84 ml) or 3–4 sprays/nostril/day and
4–8 mg (0.2–0.4 ml) or 2–4 drops/eye/day.
During the whole observation period patients were
advised by the investigator not to use any other form of
drugs, e.g., oral antihistamines for treating their symptoms
of SAR.
Outcome parameters
The patients’ demographic data were collected on day 0.
The daily allergen exposure was determined by means of
the weather score (mean of single scores “sunny” 1,
“cloudy” 0.5 and/or “rainy” 0) and whether patients were
able to stay outside during the day or sleep with an open
window during the night, as described in Weston et al. [8].
A record of the number of sprays/nare/day or drops or
sprays/eye/day, was kept, reXecting the compliance of the
patients.
After application of the particular medication, the dura-
tion till the onset of action was noted by the patients (<5, 5–
10, 10–30, 30–60 min, 1–2, 2–4, 4–8, no onset of action).
To assess eYcacy, patients daily rated their nasal (rhi-
norrhea, blocked nose, sneezing, itching) and conjunctival
(redness, itching, tearing) symptoms on a discrete ordinal
scale (0 no, 1 mild, 2 moderate, 3 severe symptoms). Val-
ues were added up into the total nasal symptom score
(NSS) and conjunctival symptom score (CSS), respec-
tively, which were in turn summed into the global rhino-
conjunctival-score (RCSS). To further evaluate the eYcacy
objectively, the principal investigator conducted a rhinos-
copy at visits 1 and 2 and scored the rinorrhea, redness and
oedema on the rhinoscopic score (0 no, 1 mild, 2 severe).
Redness was evaluated by the investigator who used a col-
our-calibrated video endoscope and recorded the images.
No decongestants were used for assessment of oedema as
they may have interfered with the evaluation of the parame-
ter blocked nose.
The Nasal-Spray-Sensory-Scale [11] and the Eye-Drops/
Spray-Sensory-Scale were used to investigate the tolerabil-
ity of the medications by asking questions about the sensa-
tion perceived by patients immediately and 2 min after
application, done by marking a Visual Analogue ScaleEur Arch Otorhinolaryngol (2012) 269:495–502 497
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(VAS) (0 worst evaluation, 100 best evaluation). This was
compared at visits 1 and 2, looking for improved tolerabil-
ity and decreased negative sensations.
The safety was assessed through precise documentation
of the side eVects.
Using the by Mösges et al. validated German Adapted
Version (GAV) of the RHINASTHMA-quality-of-life-
scale [12, 13] the therapy’s impact on QoL could be cap-
tured, by assessing 42 major symptoms and problems of
SAR before and after treatment on a 4-point-scale (where 0
insigniWcant, and 3 very signiWcant). Additionally, patients
evaluated their daily subjective state of health and quality
of sleep (Visual Analogue Scale: 0 very bad, 100 very
good).
Statistical methods
Statistical analysis was conducted using SPSS 18 for Win-
dows. Data were entered twice to reduce data entry errors
and check for plausibility. Unavailable data were treated as
“missing values” or substituted by the “last value carried
forward” method for calculating the area under the curve
(AUC).
To quantitatively describe the main study population
features, descriptive statistics were used. After checking for
normal distribution using the Kolmogorov–Smirnov test,
the diVerences for paired and unpaired variables not
normally distributed were tested for signiWcance using the
Wilcoxon and Kruskal–Wallis test, respectively, with sig-
niWcance deWned at p <0 . 0 5 .
Results
Homogeneity of treated groups
In total, 33 women and 39 men aged 18–69 years
(mean = 39.5 years) were divided into three treatment
groups, which had statistically homogenous demographic
data (Table 1), allergy diagnoses (SAR, PAR, Asthma,
mono- or poly-allergy) (Table 2), symptom scores, allergen
exposure, compliance and life quality at the beginning of
the study (Table 3). During the assessment period none of
the patients under observation used any other topic or sys-
temic anti-allergy medication.
Onset of action
A fast onset of action was noticed after nasal sprays appli-
cation in all groups. Within the Wrst hour, 70.8% of the
CGC group, 66.7% of the LTC group and 91.7% of the
LNM-treated patients felt the eVect onset. Moreover, within
5 min of application, 12.5% of the CGC group, 16.7% of
the LTC group and 8.3% of the LNM group felt the medi-
cation taking eVect. In all groups, 45.8% of the patients felt
the action onset after 5-15 min (Fig. 1).
For the Tears Again drops, 37.5%, and with Cromogly-
cate drops, 66.7% of the patients noticed an onset of action
Table 1 Demographic data
LNM LTC CGC
Number of patients 24 24 24
Sex (male/female) 14/10 13/11 12/12
Mean age (years) 39 § 9.1 40 § 16.3 40 § 15.3
Mean height (cm) 177 § 91 7 6 § 10 174 § 9
Mean weight (kg) 86 § 17.63 80 § 16.55 79.9 § 17.79
Table 2 Allergy diagnoses
LNM LTC CGC
Number of patients 24 24 24
SAR (number/%) 24/100.0 24/100.0 24/100.0
PAR (number/%) 8/33.3 4/16.6 7/29.2
Asthma (number/%) 4/16.7 2/8.3 1/4.2
Mono-allergy 16 20 17
Poly-allergy 8 4 7
Table 3 Comparison of symp-
tom scores and quality of life at 
inclusion (Kruskal–Wallis test)
p values
Nasal score 0.051
Conjunctival score 0.760
Rhinoconjunctival 
score
0.427
Rhinoscopic score 0.055
Quality of life 0.172
Fig. 1 Development of the onset of action of the nasal sprays
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within the Wrst hour after application. However, 25% of
Tears Again users and 12.5% of Cromoglycate eye drops
users felt an onset of action within 5 min (Fig. 2).
EYcacy
Treatment with LNM achieved signiWcant improvement of
the NSS (p < 0.001) and CSS (p = 0.05) and the RCSS was
resultantly signiWcantly reduced from 8.54 to 5.83
(p = 0.01) (Table 4). Similarly, CGC therapy signiWcantly
reduced both the NSS (p = 0.005) and CSS (p = 0.002) and
hence the RCSS from 7.88 to 4.83 (p =0 . 0 0 1 ) ,  ( F i g .2). On
the other hand, LTC therapy signiWcantly improved only
the NSS (p = 0.045), leading to insigniWcant reduction of
the RCSS from 7.00 to 5.57 (p = 0.064). All nasal sprays
lead to rapid symptom reduction within 2 days, after which
the RCSS for all treatment groups oscillated around 5.0
(Fig. 3).
To compare symptom reduction between groups, the
weekly NSS, CSS and RCSS were baseline-adjusted and
the AUC calculated. The resultant improvement in the
global RCSS (p = 0.781), NSS (p = 0.607) and CSS
(p = 0.748) was similar for all groups. Symptom reduction
with liposomal monotherapy and combination therapy
was equal to conventional Cromoglycate treatment
(p >0 . 0 5 ;  T a b l e5). The eYcacy of LNM and CGC ther-
apy is conWrmed through the signiWcant reduction of the
rhinoscopic scores (LNM, p =0 . 0 1 0 ;  C G C ,  p =0 . 0 0 1 ) ,
which was insigniWcantly reduced with LTC therapy
(p =0 . 5 4 1 ) .
In order to ease interpretation of the results and to be
conWdent that the changes in practice will be of perceptible
beneWt to the patient, the distribution-based minimal clinically
Fig. 2 Development of the onset of action of eye spray/drops
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Table 4 EYcacy of symptom reduction (Wilcoxon test)
LNM LTC CGC
Symptom score p values Symptom score p values Symptom score p values
Nasal score day 0 6.08 § 2.205 <0.001 4.38 § 2.223 0.045 5.21 § 2.021 0.005
Nasal score day 7 4.13 § 1.985 3.48 § 1.928 3.50 § 2.246
Conjunctival score day 0 2.46 § 1.911 0.050 2.63 § 1.498 0.167 2.67 § 1.659 0.002
Conjunctival score day 7 1.71 § 1.459 2.09 § 1.379 1.33 § 1.049
Rhinoconjunctival score day 0 8.54 § 3.945 <0.001 7.00 § 3.217 0.064 7.88 § 3.392 0.001
Rhinoconjunctival score day 7 5.83 § 2.973 5.57 § 2.694 4.83 § 2.884
Rhinoscopic score day 0 4.08 § 1.213 0.010 3.38 § 0.824 0.541 3.92 § 1.060 0.001
Rhinoscopic score day 7 3.25 § 1.073 3.26 § 1.176 2.75 § 1.189
Fig. 3 Development of the rhinoconjunctival score
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Table 5 Comparison of the symptom reduction between all groups
(Kruskal–Wallis test)
p values
AUC baseline-adjusted course of the nasal 
symptom score
0.607
AUC baseline-adjusted course of the conjuncitval 
symptom score
0.748
AUC baseline-adjusted course of the rhinoconjunctival 
symptom score
0.781Eur Arch Otorhinolaryngol (2012) 269:495–502 499
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important diVerence (MCID = baseline SD £ 0.2) and the
arithmetic mean (AM) of the baseline-adjusted symptom
scores were calculated (Table 6) [14, 15].
Tolerability and safety
The analysis of the nasal-spray-sensory questionnaire
showed for LipoNasal n that the smell and taste were found
signiWcantly inferior compared with the Cromoglycate
nasal spray (p = < 0.001) at the beginning of the study
week. In contrast, errhine (p = 0.129), irritation 2 min after
application (p = 0.251) and the amount of drug (p = 0.221),
reaching the nose and fauces was equal for all nasal sprays
(Table 7).
The nasal-spray-sensory questionnaire was re-evaluated
on visit 2 to assess for adaptation to the sprays’ smell and
taste. This showed that LipoNasal n as monotherapy had
signiWcantly better tolerated smell intensity (p = 0.043);
and as combination therapy, a signiWcantly less bitter taste
(p = 0.042) and irritation (p = 0.046) and more drug distri-
bution after 2 min (p = 0.020). With Cromoglycate nasal
spray, patients did not Wnd any signiWcant diVerence.
The analysis of the eye-pray/drops-sensory-scale at visit
1 illustrated for Cromoglycate eye drops better initial
results for eye moisturization, overall impression, and over-
all impression 2 min after application. Tears Again eye
spray received a better evaluation for the other six items,
like adverse eVect on vision and eye irritation (Table 8).
Patients treated with Tears Again recognized a stronger
visual blurring (p = 0.036) on visit 2, in contrast to Cromo-
glycate eye drop users, who felt less eye irritation
(p =0 . 0 0 5 ) .
All treatments were safe and no adverse reactions were
observed during the treatment period.
Quality of life
After within-group (Table 9; p > 0.05) and inter-compari-
son (Table 10; p = 0.196) of all treatment groups, it was
found that the global score of the RHINASTHMA quality-
of-life scale did not improve signiWcantly. The subjective
feeling improved in all groups; this was signiWcant only for
the LNM (p = 0.005) and CGC groups (p =0 . 0 0 4 ) .  T h e
quality of sleep did improve signiWcantly in the LNM group
(p = 0.05), but not in the LTC (p =0 . 2 3 6 )  a n d  C G C
(p = 0.284) groups.
Discussion
Treatment with liposomes: a possible therapy concept
The World Health Organisation’s Allergic rhinitis and its
impact on asthma (ARIA) guidelines provide a progressive
Table 6 Comparison of the changes in symptom scores during the
observation period to the MCID
AMb arithmetic mean baseline-adjusted (day 0–7), bSD baseline stan-
dard deviation, MCID minimal clinically important diVerence
(MCID = baseline SD £ 0.2)
LNM LTC CGC
NSS
AMb ¡1.72 ¡1.09 ¡1.58
bSD §2.205 §2.223 §2.021
MCID §0.44 §0.44 §0.40
CSS
AMb ¡0.73 ¡0.68 ¡1.01
bSD §1.911 §1.498 §1.659
MCID §0.38 §0.30 §0.33
RCSS
AMb ¡2.45 ¡1.77 ¡2.60
bSD §3.845 §3.217 §3.392
MCID §0.77 §0.64 §0.68
Table 7 Four of 14 items of the 
nasal-spray-sensory-scale on 
visit 1; p values calculated by 
Kruskal–Wallis test
LNM LTC CGC p values
Intensity of aroma 44 § 30.6 36 § 22.9 84 § 19.9 <0.001
Errhine 84 § 25.7 77 § 21.8 83 § 20.9 0.129
Irritation (burning, irritation) 
(2 min after application)
81 § 20.9 74 § 26.5 85 § 20.8 0.251
Amount of drug, which 
reaches nose and fauces
67 § 23.7 61 § 20.7 71 § 28.4 0.221
Table 8 Four of 14 items of the eye-spray/drops-sensory-scale on
visit 1; p values calculated by Wilcoxon test
LTC CGC p values
Overall impression 57 § 20.4 75 § 21.9 0.004
Adverse eVect of vision 83 § 18.0 70 § 21.6 0.635
Irritation of the eye (burning, 
irritation)
80 § 24.0 74 § 25.6 0.192
Amount of drug, which 
reaches nose and fauces
95 § 9.9 84 § 25.4 0.088500 Eur Arch Otorhinolaryngol (2012) 269:495–502
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algorithm for SAR treatment recommending systemic or
topical antihistaminics or glucocorticoides with cromones
as an alternative and then if necessary, leukotriene antago-
nists and decongestants [16].
Kaschke [17] published that 64% of SAR patients have
‘cortisone phobia’ and only 31% apply long-term topical
steroid treatment, preferring alternative treatments because
of negative experiences with steroids [18]. Some patients
may have reservations towards using chemical prepara-
tions. Liposomes are thus promising, non-chemical, non-
steroid alternatives.
An explanation for liposome mechanism of action
assumes that they stabilize the nasal mucosal barrier and
treat its dysfunction by integrating in the damaged cell
membrane [19] so that fewer allergens can pass through.
Andersson [9] assumes that liposomes absorb and thus
inactivate allergens [20].
According to the experiences of some patients, liposo-
mal eye sprays used for dry eye can also reduce SAR symp-
toms. The anti-inXammatory eVect was also observed in
earlier studies, in which eyelid inXammations in dry eye
healed strikingly fast, which was explained through the
antioxidatant eVect of phosphatidylcholin [21].
EYcacy
Nasal symptom scores at baseline were numerically diVer-
ent between the three groups and this diVerence came close
to statistical signiWcance with a p value of 0.051. With
regard to the diVerent symptom levels in the groups, “mod-
erate” for LNM, “mild-moderate” for CGC and “mild” for
LTC it is not feasible to assess the relative improvement in
% compared with baseline.
For an eYcacy claim in allergic rhinoconjunctivitis the
EMEA demands that the eYcacy for the nasal and eye-
symptom-score is discussed separately, e.g., as the symp-
tom-score is a composite scale. Moreover, the overall eVect
should be balanced so that, e.g., the overall outcome is not
driven by a large eVect on a limited number of items and no
eVect or even worsening in the other items of the scale.
Also the symptom reduction should be expressed with
regard to the minimal clinically change for the outcome
parameter [22]. As recommended by Cohen [15], any
change over and above an arbitrary limit of 0.2 times the
baseline standard deviation (SD) can be interpreted as clini-
cally meaningful (minimum clinically important diVerence
MCID). In all treatment groups the improvement exceeds
the MCID so that the assumption of eYcacy can be main-
tained (Table 6). As recommended by Barnes [14], compar-
ing the individual changes from baseline in the NSS during
the entire observation period of all groups to a MCID of
0.55 units also provides a clinically meaningful change for
all patients.
Onset of action
The rapid eVect onset achieved within an hour with all three
therapy options was not surprising, considering it was
recorded in 2/3 of patients in earlier studies [10, 23].
Tolerability and safety
It was found that patients habituate to the intensity of the
smell of the liposomal nasal spray and tolerated it signiW-
cantly better at visit 2, possibly due to the smaller menthol
fraction. Nevertheless, this smaller menthol fraction may
have contributed to the favourable eVect on nasal blockage.
Both the Cromoglycate and LipoNasal n were well toler-
ated, which is important to improve compliance and suc-
cessfully reduce symptoms. No adverse reactions were
observed at all.
Quality of life
None of the treatment options caused a signiWcant improve-
ment of the quality of life, possibly because allergen expo-
sure during the study duration reached almost 80% of the
total exposure possible. Also other studies [24] investigat-
ing guideline accordant drugs with a proven eYcacy, e.g.,
the second-generation anithistamine Loratadine, demon-
strate no improved QoL score after drug administration.
Nevertheless, the subjective feeling of patients improved,
underlining the eVective symptom reduction of all treat-
ment options.
Table 9 Global score of RHINASTHMA-quality of life scale; p values calculated by Wilcoxon test
LNM LTC CGC
Symptom score p values Symptom score p values Symptom score p values
RHINASTHMA global score visit 1 1.56 § 0.444 0.130 1.80 § 0.305 0.082 1.76 § 0.440 0.082
RHINASTHMA global score visit 2 1.66 § 0.469 1.89 § 0.393 1.75 § 0.465
Table 10 Comparison of the 
RHINASTHMA global score on 
visit one and two for all groups 
(Mann–Whitney U test)
p values
Visit 1 0.172
Visit 2 0.196Eur Arch Otorhinolaryngol (2012) 269:495–502 501
123
Conclusion
It is evident from this study that the prescription-free lipo-
somal-based sprays, given as monotherapy or combination
therapy, provide new treatment options for both NSS and
conjunctival symptoms caused by SAR. Their eYcacy,
onset of action and tolerability do not diVer signiWcantly
from cromoglycate combination therapy, which is known to
be an evidence-based, however, weakly eVective allergy
medication. In all three groups the improvement of the NSS
and CSSs exceeds the MCID. The new formulation, with
decreased menthol content, provides patients suVering from
SAR with a more tolerable liposomal nasal spray.
To sum up, the non-pharmaceutical alternative of
liposomes has an appreciable potential to reduce SAR
symptoms comparable to the established cromoglycate
combination therapy. Thus, patients with reservations con-
cerning pharmaceutical treatment can be treated eVectively
with liposomes for SAR. Further research is needed to
reveal the mechanism of action of liposomes in SAR.
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